Özet:

OBJECTIVES In our study, we aimed to evaluate the clinical characteristics and treatment outcomes of patients with metastatic renal cell carcinoma (mRCC). METHODS Data of 105 mRCC patients treated and monitored at our center between 2006–2013 was studied retrospectively. RESULTS Median age was 57 years. Of the patients, 67% was male. The rate of non-clear cell subtype was 13%. Seventy-one percent of the patients received sunitinib without interruption where objective response rate was 20%. The most common grade 3–4 toxicity was anemia (15%). Median progression-free survival (PFS) and overall survival (OS) were 9 and 21 months, respectively. In multivariate analysis, sunitinib treatment unresponsiveness (p<0.001) had a negative impact on PFS whereas treatment unresponsiveness (p<0.001) and absence of surgery (p=0.05) were the factors that decreased OS. CONCLUSION Median duration of PFS and OS was consistent with the literature despite the fact that relatively poor prognostic group of patients were included and more dose modifications were needed due to toxicicity in our study.

Anahtar Kelimeler: